

RECEIVED

CAU 1643

AUG 10 2001

Attorney Docket No. CPMC-010/00US

TECH CENTER 1600/2900

PATENT



Express Mail Label Number:

EL514036848US

Date of Deposit:

AUGUST 6, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents and Trademarks, Washington, DC 20231.

Date:

Aug 6, 2001

By:

Vikki L. Athen
VIKKI L. ATHEN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of SHANAZ H. DAIRKEE, et al.

Serial No.: 09/816,460

Examiner: Not Yet Assigned

Confirmation No.: 6434

Art Unit: 1643

Filed: March 23, 2001

For: PROGNOSTIC METHODS FOR BREAST CANCER

Attn: Manager, Application Branch
Commissioner for Patents and Trademarks
Washington, D.C. 20231

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCES**

In response to the Notice to Comply with Requirements for Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed July 25, 2001, transmitted herewith are:

- ☒ [X] paper copy of the "Sequence Listing";
- ☒ [X] copy of the "Sequence Listing" in computer readable form on a:
 - ☒ [X] 3 1/2" floppy disk;
 - ☐ [] 5 1/4" floppy disk;
- ☒ [X] Preliminary amendment directing the entry of the Sequence Listing into the application;
- ☒ [X] Statement under 1.821(f).

The content of the copy in computer readable form is identical to the content of the paper copy of the "Sequence Listing" and includes no new matter.

This submission includes no new matter.


The Commissioner is hereby authorized to charge any underpayment of the following fees associated with this communication, or credit any overpayment to Deposit Account No. 03-3117:

- ☒ Any national application filing fees under 37 CFR 1.16.
- ☒ Any patent application processing fees under 37 CFR 1.17.

Cooley Godward LLP
Attn: Patent Group
Five Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306-2155
Tel: (650) 843-5000
Fax: (650) 857-0663
ML:hh

Respectfully submitted,
COOLEY GODWARD LLP

By:



Marcella Lillis, Ph.D.
Reg. No. 36,583





UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov


APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/816,460	03/23/2001	Shanaz H. Dairkee	CPMC-010/00US

23419
COOLEY GODWARD, LLP
3000 EL CAMINO REAL
5 PALO ALTO SQUARE
PALO ALTO, CA 94306



CONFIRMATION NO. 6434

FORMALITIES LETTER



OC000000006338617

Date Mailed: 07/25/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

RECEIVED

AUG 10 2001

TECH CENTER 1600/2900

This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

nl
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE